Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) has secured a significant contract with a major London transport operator to implement its Intelligent Fingerprinting Drug Screening System across 14 operational sites serving over 4,400 staff. The transport operator manages a fleet of 1,400+ low-emission vehicles and serves more than one million passengers daily.

The company's drug testing technology is currently utilized by 450+ accounts across 24 countries through 18 distribution partners. INBS is actively expanding globally and pursuing FDA clearance for planned entry into the U.S. market in 2025.

Positive

• Secured major contract with London transport operator covering 14 sites and 4,400 staff
• Strong global presence with 450+ accounts in 24 countries and 18 distribution partners
• Technology offers cost savings and improved workforce efficiency through rapid testing
• Planned expansion into U.S. market in 2025 pending FDA clearance

Negative

• FDA regulatory clearance still pending for U.S. market entry

Insights

Contract Analysis Specialist

INBS secured major London transport contract for drug testing system, expanding global footprint while awaiting FDA approval for US market entry.

Intelligent Bio Solutions (INBS) has secured a significant commercial milestone by winning a tender with one of London's largest public transport operators. The contract's scope is substantial – covering 14 operational sites, 4,400 staff, and supporting a bus network that serves over one million daily passengers with a modern fleet of 1,400+ low-emission vehicles.

The selection of INBS's Intelligent Fingerprinting Drug Screening System demonstrates strong market validation for their technology in safety-critical environments. The transport operator's decision likely hinged on the system's ability to minimize workforce downtime during testing – a crucial efficiency factor in transportation operations where scheduling is tightly controlled and staff availability directly impacts service delivery.

This contract adds to INBS's already established global presence of 450 accounts across 24 countries. The company's distribution network of 18 partners positions them for continued international expansion across multiple regions. The mention of pending FDA regulatory clearance signals that INBS is preparing for U.S. market entry in 2025, which represents a substantial growth opportunity given the size of the American workplace testing market.

For a Nasdaq-listed company like INBS, securing contracts with major infrastructure operators demonstrates commercial traction and ability to compete in enterprise-level procurement processes. The contract's value wasn't disclosed, but implementation across such a large operation should provide meaningful revenue contribution while serving as a reference customer for additional transportation sector sales.

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London's largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff.

INBS's Intelligent Fingerprinting Drug Screening System will be deployed across a multi-garage bus network that carries over one million passengers daily. The fleet includes more than 1,400 low-emission vehicles, including a mix of hybrid, electric, and hydrogen-powered buses.

“Winning this tender says a lot about the strength of our technology,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We offer a system that supports rapid drug testing at scale, meaning less people out of action for less time. This minimizes financial loss associated with long wait times and improves overall workforce efficiency. The rapidly rising popularity of our solution is testament to the many benefits it offers businesses of all sizes; from a greater suggestion of impairment and reduced risk to cost savings and a more dignified approach.”

The decision to adopt the Company’s innovative testing system aligns with the operator's ongoing investment in safety, people and modernization. With a purpose-built engineering and logistics facility serving its expansive fleet, the operator represents a forward-thinking leader in transport.

INBS’s drug testing technology is adopted by over 450 accounts in 24 countries, with 18 distribution partners expanding its global reach. In addition to continued expansion throughout the UK, the Company is actively growing its presence across Europe, the Middle East and Africa, Asia Pacific and the United States (U.S.). Regulatory clearance from the U.S. Food and Drug Administration (FDA) remains a priority as the Company plans to enter the U.S. market in 2025.

About Intelligent Bio Solutions Inc. 

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit http://www.ibs.inc/

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact
Intelligent Bio Solutions Inc. 
info@ibs.inc  
LinkedIn | Twitter 

Investor & Media Contact
Valter Pinto, Managing Director 
KCSA Strategic Communications 
PH: (212) 896-1254 
INBS@kcsa.com

FAQ

What is the size of the new contract secured by Intelligent Bio Solutions (INBS)?

The contract covers 14 operational sites in greater London, serving over 4,400 staff and a fleet of more than 1,400 low-emission vehicles that transport over one million passengers daily.

How many customers currently use INBS's drug testing technology?

INBS's drug testing technology is currently used by over 450 accounts across 24 countries, with distribution through 18 partners globally.

When does Intelligent Bio Solutions plan to enter the U.S. market?

INBS plans to enter the U.S. market in 2025, pending regulatory clearance from the FDA.

What are the key benefits of INBS's Intelligent Fingerprinting Drug Screening System?

The system offers rapid drug testing at scale, reducing employee downtime, minimizing financial losses from wait times, improving workforce efficiency, and providing a more dignified testing approach.

How many distribution partners does Intelligent Bio Solutions have globally?

INBS has 18 distribution partners expanding its reach across Europe, the Middle East and Africa, Asia Pacific, and plans for the United States.